[go: up one dir, main page]

JOP20220043A1 - بروتين كابسيد vp1 معدل معزول من aav5 - Google Patents

بروتين كابسيد vp1 معدل معزول من aav5

Info

Publication number
JOP20220043A1
JOP20220043A1 JOP/2022/0043A JOP20220043A JOP20220043A1 JO P20220043 A1 JOP20220043 A1 JO P20220043A1 JO P20220043 A JOP20220043 A JO P20220043A JO P20220043 A1 JOP20220043 A1 JO P20220043A1
Authority
JO
Jordan
Prior art keywords
aav5
capsid protein
isolated modified
capsid
relates
Prior art date
Application number
JOP/2022/0043A
Other languages
English (en)
Inventor
Elena Victorovna Iurlova
Alexandr Vladimirovich Prokofyev
Mariya Pavlovna Perepelkina
Anna Nikolaevna Strelkova
Pavel Mikhailovich Gershovich
Aleksandr Vladimirovich Karabelskii
Dmitrij Aleksandrovich Madera
Dmitry Valentinovich Morozov
Original Assignee
Llc Anabion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Llc Anabion filed Critical Llc Anabion
Publication of JOP20220043A1 publication Critical patent/JOP20220043A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق هذا الطلب بمجالات العلاج الجيني gene therapy والبيولوجيا الجزيئية molecular biology. بشكل أكثر تحديدًا، يتعلق الاختراع الحالي ببروتينVP1 protein المعزول المتغير من النمط المصلي 5 virus serotype 5 (AAV5) للفيروس المرتبط بالغدة adeno-associated virus والذي يشتمل على واحد أو أكثر من بدائل الأحماض الأمينية amino acid مقارنةً ببروتين VP1 من النوع البريwild-type AAV5 كابسيد capsid، مما يزيد من كفاءة التنبيغ transduction efficiency، وكذلك إلى كابسيد وناقل قائم عليها.
JOP/2022/0043A 2019-08-22 2020-08-21 بروتين كابسيد vp1 معدل معزول من aav5 JOP20220043A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019126509A RU2751592C2 (ru) 2019-08-22 2019-08-22 Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
PCT/RU2020/000445 WO2021034222A1 (ru) 2019-08-22 2020-08-21 Выделенный модифицированный белок vp1 капсида aav5

Publications (1)

Publication Number Publication Date
JOP20220043A1 true JOP20220043A1 (ar) 2023-01-30

Family

ID=74660332

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0043A JOP20220043A1 (ar) 2019-08-22 2020-08-21 بروتين كابسيد vp1 معدل معزول من aav5

Country Status (20)

Country Link
US (1) US20220306696A1 (ar)
EP (1) EP4019642A4 (ar)
JP (1) JP2022545121A (ar)
KR (1) KR20220158674A (ar)
CN (1) CN114981444B (ar)
AR (1) AR119869A1 (ar)
AU (1) AU2020331882A1 (ar)
BR (1) BR112022003389A2 (ar)
CA (1) CA3148964A1 (ar)
CO (1) CO2022001833A2 (ar)
EC (1) ECSP22021725A (ar)
IL (1) IL290802A (ar)
JO (1) JOP20220043A1 (ar)
MA (1) MA56142B1 (ar)
MX (1) MX2022002184A (ar)
PE (1) PE20221254A1 (ar)
PH (1) PH12022550434A1 (ar)
RU (1) RU2751592C2 (ar)
TW (1) TW202120690A (ar)
WO (1) WO2021034222A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3135609A1 (en) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
CN113121654B (zh) * 2021-04-19 2023-11-17 信念医药科技(上海)有限公司 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体
AR126839A1 (es) * 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
AR126840A1 (es) 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
WO2025040185A1 (zh) * 2023-11-29 2025-02-27 广州译码基因科技有限公司 可提高aav病毒神经靶向性的衣壳蛋白突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
ES2717377T3 (es) * 2001-12-17 2019-06-20 Univ Pennsylvania Secuencias de serotipo 8 de virus adeno-asociado (AAV), vectores que las contienen y usos de las mismas
US9193956B2 (en) 2011-04-22 2015-11-24 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
BR122021020419B1 (pt) 2012-04-18 2023-01-17 The Children's Hospital Of Philadelphia Vetor de vírus adeno-associado (aav) que compreende uma proteína de capsídeo vp1, composições farmacêuticas compreendendo o mesmo, e seus usos
CA2919103C (en) * 2013-07-22 2023-10-10 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
US10081659B2 (en) * 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
SG10202107733QA (en) * 2015-09-28 2021-09-29 Univ North Carolina Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017201121A1 (en) * 2016-05-17 2017-11-23 University Of Florida Research Foundation, Inc. Recombinant aav for gene therapy in lungs
CA3135609A1 (en) * 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
RU2761879C1 (ru) * 2021-07-27 2021-12-13 Закрытое Акционерное Общество "Биокад" Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2

Also Published As

Publication number Publication date
US20220306696A1 (en) 2022-09-29
CO2022001833A2 (es) 2022-08-09
RU2019126509A3 (ar) 2021-06-04
BR112022003389A2 (pt) 2022-05-17
IL290802A (en) 2022-04-01
RU2019126509A (ru) 2021-06-04
JP2022545121A (ja) 2022-10-25
WO2021034222A9 (ru) 2021-04-22
PE20221254A1 (es) 2022-08-16
EP4019642A4 (en) 2023-09-06
TW202120690A (zh) 2021-06-01
WO2021034222A1 (ru) 2021-02-25
PH12022550434A1 (en) 2024-02-19
MX2022002184A (es) 2022-05-24
RU2751592C2 (ru) 2021-07-15
CN114981444B (zh) 2025-05-27
AR119869A1 (es) 2022-01-19
CA3148964A1 (en) 2021-02-25
AU2020331882A1 (en) 2022-11-03
EP4019642A1 (en) 2022-06-29
KR20220158674A (ko) 2022-12-01
ECSP22021725A (es) 2022-08-31
CN114981444A (zh) 2022-08-30
MA56142B1 (fr) 2023-09-27
MA56142A1 (fr) 2023-05-31

Similar Documents

Publication Publication Date Title
PH12022550434A1 (en) Isolated modified vp1 capsid protein of aav5
SA519402565B1 (ar) F ناقل فرع حيوي لفيروس مرتبط بالغدة جديد واستخداماته
TN2020000187A1 (en) Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
PH12020551938A1 (en) Liver targeting adeno-associated viral vectors
EP3597760A3 (en) Adeno-associated virus vector
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
NZ783341A (en) Modified capsid proteins for enhanced delivery of parvovirus vectors
WO2019169004A8 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA202091712A1 (ru) МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ
MX2023012722A (es) Capsides de aav y usos de las mismas.
MX2024002199A (es) Proteina vp1 modificada y aislada de la capside del virus adenoasociado del serotipo 5 (aav5), capside y vector basados en esta.
MX2024002379A (es) Cápsides y vectores de aav modificados.
EA201990955A1 (ru) Разработка капсидов aav
MX2024002200A (es) Metodo para obtener una capside de virus adenoasociado modificada.
WO2025035137A3 (en) Synthetic helper genes for enhancing viral production
MX2023010350A (es) Acido nucleico optimizado por codones que codifica la proteina del factor de coagulacion ix, y su uso.
ECSP24013002A (es) Proteína vp1 de la cápsida aav9 modificada aislada
WO2023242633A3 (en) Recombinant aav capsid proteins
WO2023194796A3 (en) Recombinant aav capsid proteins
NZ749467A (en) Novel adeno-associated virus capsid proteins
EA201992023A1 (ru) Вектор на основе аденоассоциированного вируса (aav) клады f и его применения